(精编)【体外膜肺ECMO精品课件】What can we do more for the cost-effectiveness of management of AKI教学课件.pptVIP

What can we do more for the cost-effectiveness of management of AKI? 鄭昌錡* Siew ED, et al. JASN 2011 Phases of clinical biomarker evaluation and AKI studies * Comparative effectiveness research (CER) 比較效果研究 * The generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, or to improve the delivery of care. Definition * Novel biomarkers in AKI Parikh CR et al. CCM 2008 Chen YC, Fang JT, Yang CW. Taiwan Crit Care Med 2009 * A quality-adjusted life-year (QALY) takes into account both